The ambition to improve the quality of life of polypharmacy patients – most of whom are elderly – has driven us to translate the latest scientific findings in pharmacogenetics into routine clinical practice. With the PGXperts System, we offer a fast, reliable and cost-effective system that supports physicians and healthcare professionals in complex issues of drug therapy selection and drug therapy management.
With the PGXperts System, we have developed a comprehensive clinical decision support system to review complex medication scenarios. It takes the patient’s personal genetic predisposition with regard to metabolism, transport and hypersensitivity, the individual medication and its dosage, as well as the patient’s lifestyle and accompanying risk factors into account. With this innovative medical product, we enable individually tailored pharmacotherapy.
www.pgxperts.com
Every person metabolises individual drugs differently. Therefore, the PGXperts System takes into account the patient’s genetic predisposition by providing an individual pharmacogenetic interpretation. It transforms evidence-based data into best practice care and services for individual stakeholders in the context of personalised medication.
Pharmacogenetics (PGx) investigates the interaction of drugs with the different genetic characteristics of each individual. As early as the 1950s, the Heidelberg human geneticist Friedrich Vogel used clinical observations to identify the interplay between a person’s genetic makeup and his or her personal response to a drug. He coined the term “pharmacogenetics” for this phenomenon.
In the human body, a complex system of enzymes and other transport proteins as well as receptor structures control the uptake of a drug, its distribution in the body, its biochemical conversion and degradation, and its excretion. A person’s genetic makeup determines the individual enzyme equipment that a person has available to process active substances. Genetic variations affect the functioning of these enzymes and may play a role in the overall mechanism of drug metabolism and drug action.
The genetic variations determining metabolism are specific to each drug. As a result, the standard dosage of a drug may not achieve the desired therapeutic effect. Reduced excretion, on the other hand, can quickly lead to overdoses with corresponding complaints and side effects.
By determining a metabolisation type, pharmacogenetics allows prediction of the individual effect of a drug. In medicine, the term metabolisation refers to the biochemical conversion or degradation of a substance by the body’s own enzyme systems.
PGXperts was developed in close cooperation with our scientific advisory board. This ensures medical accuracy, routine applicability and commercial viability. The members of the scientific advisory board support us in the development of new features and in the planning of clinical studies.
Matthias Herforth
Dr. Per Hoffmann
Prof. Dr. Stephanie E. Combs
Dr. Bernd Hensel
Herna Munoz-Galeano
Prof. Dr. Dr. Ingolf Cascorbi
Prof. Dr. Frank-Ulrich Fricke
Prof. Dr. Markus Nöthen
Prof. Dr. Dr. Ingolf Cascorbi
Prof. Dr. Stephanie E. Combs
Prof. Dr. Markus Nöthen
Director Institute of Human Genetics (University Hospital Bonn)
Prof. Dr. Frank-Ulrich Fricke
Dean of Business Administration – Focus on Health Economics (Nuremberg University of Technology)
Dr. Bernd Hensel
Former Head of Geriatric Rehabilitation Department (City of Nuremberg)
Dr. Per Hoffmann
Head of Commercial Operations – Genomics (Life&Brain Research Center Bonn)
Dr. Georg Metzger (Not shown in the picture)
